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Introduction/Background. Nonmetastatic castrate resistant prostate cancer (CRPC) is a challenging disease state. The objective of
this study was to evaluate the eﬃcacy and tolerability of bevacizumab in nonmetastatic CRPC patients. Patients. Patients with
prostate cancer who developed PSA recurrence after local therapy were included if they had absence of bone or visceral metastases
and PSA progression despite androgen deprivation therapy. Methods. Bevacizumab 10mg/kg intravenously was administered
every 14 days until PSA progression, development of metastasis, or unacceptable toxicity. Results. 15 patients were enrolled and
treated with bevacizumab for a median duration of 3.1 months. Median baseline PSA was 27ng/mL, and seven patients had
Gleason Score ≥8. Five patients had declined in PSA during the treatment. Median PSA doubling time was prolonged from 4.7
months pretreatment to 6.5 months. Median time to PSA progression and new metastasis were 2.8 and 7.9 months, respectively.
There were three grade 3 adverse events (one proteinuria and two hypertension) and one pulmonary embolism. There was no
treatment-related mortality. Conclusion. Bevacizumab therapy had minimal impact on the disease course of nonmetastatic CRPC,
and investigation of novel strategies is needed.
1.Background
Approximately 30–40% of localized prostate-cancer patients
develop biochemical relapse at 10 years after deﬁnitive
l o c a lt r e a t m e n t s[ 1–3]. Case series reports indicate that
patients with prostate speciﬁc antigen (PSA) relapse will
develop metastatic disease within a median duration of
eight years, after biochemical failure [4]. Patients with
high Gleason score (≥8), rapid PSA doubling time, and/or
earlier PSA relapse after local treatment have higher risk of
progression to metastatic disease during their lifespan and
higher mortality [4, 5].
Currently no systemic therapy has proven eﬃcacy in
delaying the appearance of metastatic disease or improving
survival after biochemical relapse (PSA failure). LHRH
agonists are the most widely used agents in this setting.
Although there is no solid evidence to support this strategy,
randomized trials in metastatic disease certainly suggest
that immediate use of androgen deprivation therapy (ADT)
is associated with improved disease-speciﬁc mortality and
morbidity, compared with delayed initiation of the ther-
apy [6]. Unfortunately, progression on ADT eventually
occurs, that is, nonmetastatic castrate-resistant prostate
cancer (CRPC), and after that, this patient population
is likely to continue progression to metastatic disease.
Prospective studies have shown that higher baseline PSA
and higher PSA velocity (i.e., shorter PSA doubling time)
are the independent predictors for shorter time to bone
metastasis and worse overall survival [7, 8]. A recently
reported phase III study showed that denosumab, a RANKL
monoclonal antibody, delayed time to bone metastasis by
3.7 months when compared to placebo in nonmetastatic
CRPC patients; however the impact on morbidity or overall
survival is unknown [9]. Therefore, currently there remains2 ISRN Oncology
an unmet need for evaluation of eﬀective and tolerable
agents in the therapy of non-metastatic CRPC to intervene
and alter outcomes, prior to the appearance of distant
metastases.
Bevacizumab is a fully humanized anti-VEGF mono-
clonal IgG1 antibody [10]. In phase II studies, the addition
ofbevacizumabtodocetaxeldemonstrated37–49%objective
response rates in patients who had been pretreated with
docetaxel [11, 12]. The addition of bevacizumab appeared to
besafeanddidnotincreaseseriousadverseeventsinprostate
cancerpatientsinbothmetastaticandnonmetastaticsettings
[11–13]. With the preliminary eﬃcacy data in metastatic
prostate cancer and the established tolerability of beva-
cizumab, it led to the rationale of evaluating the agent in
an earlier setting of nonmetastatic disease. The objectives
of this phase II study were to evaluate the eﬃcacy and
tolerability of bevacizumab monotherapy in non-metastatic
prostate cancer patients, with biochemical progression, after
local therapy and ADT.
2. Patients
Patients 18 years of age or older with an Eastern Cooperative
Oncology Group (ECOG) performance status of either 0 or
1 and life expectancy of at least 6 months were eligible if
they had a documented histological diagnosis of prostate
adenocarcinoma, with no evidence of bone/visceral metas-
tases, as visualized on standard imaging such as bone scan,
chestX-ray,CTscan,orMRIofabdomenandpelvis.Patients
had to have biochemical progression by prostate-speciﬁc
antigen (PSA) levels, despite being treated with androgen
deprivation therapy. PSA progression was deﬁned as 3 rising
levels, with a minimum interval of 2 weeks between each
determination. The last PSA level had to be a minimum
value of 1ng/mL, measured within two weeks prior to
registration. If the patient was on antiandrogen therapy, then
PSA progression after the withdrawal period (a minimum
of 28 days for ﬂutamide and 42 days for bicalutamide or
nilutamide) was required. Patients with a history of previous
exposure to bevacizumab were excluded and no concurrent
anticancer therapies including antiandrogen therapy and
other hormonal manipulations, except for LHRH agonists
were permitted during the study. Patients on steroids had
to discontinue them before starting bevacizumab. Patients
who were on LHRH agonists were required to continue
the use of this therapy. Bisphosphonate use was allowed
per treating physician discretion. At least 4 weeks had to
have elapsed since prior systemic therapy, except for LHRH
analogue therapy and steroids. Patients were required to use
eﬀective means of contraception. Patients with uncontrolled
hypertension(deﬁnedas systolic blood pressure >150 and/or
diastolic blood pressure >100mmHg on antihypertensive
medications), any prior history of hypertensive crisis or
hypertensive encephalopathy, New York Heart Association
(NYHA) grade 2 or greater congestive heart failure, his-
tory of myocardial infarction or unstable angina within
12 months from the study enrollment, and/or history of
stroke or transient ischemic attack within 6 months were
excluded. Patients with signiﬁcant vascular disease (e.g.,
aortic aneurysm, aortic dissection), symptomatic peripheral
vasculardisease,evidenceofbleedingdiathesisorcoagulopa-
thy,historyofabdominalﬁstula,gastrointestinalperforation,
or intra-abdominal abscess within 6 months prior to study
enrollment were also ineligible. Patients on anticoagulants
were allowed if they had been on therapy for at least 4
weeks and had no acute thromboembolic activity. Patients
had to have recovered from any major surgical procedure,
open biopsy, or signiﬁcant traumatic injury without serious,
nonhealing wound, ulcer, or bone fracture, and a minimum
time interval of 28 days must have elapsed from any major
surgery. Patients with signiﬁcant proteinuria (urine protein:
creatinine ratio ≥1.0) were excluded. Low-dose aspirin
(≤325mg/d) could be continued in subjects at high risk for
arterial thromboembolic disease.
All the patients reviewed and signed written informed
consent, and the protocol was approved by the institutional
review board of each participating hospital.
3. Treatment
Bevacizumab monotherapy was administered on an out-
patient basis at a dose of 10mg/kg intravenously every 14
days. The treatment was continued until disease progression,
intolerable toxicities, or patient withdrawal from the study.
Dose reduction of bevacizumab was not allowed. If patients
experienced any of the following adverse events (AEs),
bevacizumab was discontinued permanently and the patient
was taken oﬀ the study: grade 3 hypertension not controlled
by antihypertensive medications, grade 4 hypertension, any
grade 4 hemorrhage, grade ≥2 pulmonary and/or cranial
hemorrhage, symptomatic grade 4 venous thrombotic event,
arterial thromboembolic event of any grade, grade 4 con-
gestive heart failure, grade 4 proteinuria, gastrointestinal
perforation, wound dehiscence requiring interventions, and
any grade 4 events thought to be related to bevacizumab by
investigators. The treatment was delayed for the following
AEs: grade 3 nonpulmonary and/or non-CNS hemorrhage,
grade 3 venous thrombosis, grade 3 proteinuria, grade ≥2
bowel obstruction, and any grade 3 events. Bevacizumab
was withheld at least 2 weeks prior to any minor procedure
(e.g., dental extraction, superﬁcial skin lipoma removal)
and at least 4 weeks prior to any major surgical procedure.
The therapy was not restarted for a minimum of 4 weeks
after a major surgical procedure and until wound healing
was complete. Regardless of the reason for holding study
drug treatment, the maximum allowable length of treatment
interruption was 2 months.
4. Evaluation
Blood pressure and proteinuria were monitored every two
weeks and 4 weeks, respectively. Toxicity was evaluated every
2 weeks and PSA evaluated every 6 weeks while on therapy.
PSAwasevaluatedafterdiscontinuingtherapyataminimum
of every 3 months. Bone scan, CXR or chest CT, and CT scan
ofabdomenandpelviswereperformedevery3monthswhileISRN Oncology 3
on therapy, and after that at physician discretion. Toxicities
were graded per the National Cancer Institute Common
Terminology Criteria for Adverse Events (CTCAE) version
3.0, and PSA response was determined per the PSA working
group criteria [14]. A PSA decline ≥50%, conﬁrmed by a
second PSA value at least 4 weeks later, was considered a
PSA response if patients did not demonstrate clinical or
radiographic evidence of disease progression during this
time period. The reference PSA for these declines was
a PSA measured within 2 weeks before starting therapy.
P S Ap r o g r e s s i o nw a sd e ﬁ n e dd i ﬀerently for patients who
demonstrated a PSA response versus not. In patients whose
PSA had not decreased, progression was deﬁned as a 25%
increase over the baseline (before study) and an increase in
the absolute value PSA level by at least 1ng/mL, which was
conﬁrmed by a second value at least 4 weeks later. In patients
whosePSAhaddecreased,progressivediseasewasconsidered
to have occurred when PSA increased 25% over the nadir,
provided that the increase was a minimum of 1ng/mL and
was conﬁrmed by a second value at least 4 weeks later. In
patients whose PSA declined to 50% of baseline on study,
PSAprogressionwasdeﬁnedasa50%increaseoverthenadir
and a minimum of 1ng/mL increase, conﬁrmed by a second
value at least 4 weeks later.
5.StatisticalMethods
This single arm multi-institutional phase II trial was a pilot
study. Primary endpoints of this study were PSA response
rate, time to PSA progression (TTPP), and treatment-related
toxicities. TTPP was measured from the registration date to
the date of PSA progression. Secondary endpoints included
overall survival (OS) and time to metastatic disease which
wasmeasuredasthetimefromregistrationtotheﬁrstclinical
orradiologic appearanceofmetastases.Thesamplesizeof15
was planned to estimate the PSA response rate (or toxicity
rates) with suﬃcient precision such that the estimate will be
useful in planning a subsequent study. With N = 15, the PSA
response proportion (or a toxicity rate) could be estimated
with a standard error <0.13.
Statistical graphics were used to display the PSA response
distribution (via a waterfall plot), and the statistics of the
PSA distributions at various time points (via a multiple
box plot). Standard Kaplan-Meier estimates of the censored
TTPP,timetometastaticdisease,andtimetobonemetastasis
distributions were computed. Due to the small sample sizes,
time to event statistics (e.g., median, 6 month rate, etc.) were
estimated more conservatively using linear interpolation
among successive event times on the Kaplan-Meier curves
[15].
6. Results
6.1. Patient Characteristics. A total of 16 patients were
enrolled in the study from December, 2007 to November,
2010 in three hospitals in Detroit, Michigan in the United
States. However, one patient was never treated due to
ineligibility (uncontrolled hypertension) and excluded from
this analysis. Therefore, the results of the 15 eligible and
treated patients are reported here.
The baseline characteristics of the study participants are
summarized in Table 1. Median age was 70 years (range 51–
87 years) and 4 patients were over 80 years of age. None of
the patients had prior chemotherapy, and fourteen patients
had prior radiation as a local treatment. Seven patients had
a Gleason score of 8 or higher at diagnosis. Two patients had
PSA recurrence within two years following the completion of
their local therapy. The baseline PSA doubling time was 4.7
monthsbeforetherapy,andallthepatientshadPSAdoubling
time ≤10 months, which are associated with poor prognosis.
Median PSA prior to the initiation of bevacizumab was
27ng/mL (range 2.6–104.0), and ten patients had baseline
PSA ≥10ng/mL.
6.2. Toxicity. Fourteen patients had discontinued beva-
cizumab by the time of this analysis. Thirteen patients
discontinued the therapy due to disease progression, and
one patient discontinued bevacizumab due to occurrence
of grade 4 pulmonary embolism, which occurred during
the third cycle of treatment. No treatment-related mortality
was observed. All other treatment-related AE of grade 2 or
worse are summarized in Table 2. The most common AE was
hypertension. Two patients developed grade 3 hypertension
requiring dose adjustment of their antihypertensive drugs.
6.3. Treatment Eﬃcacy and Survival. Median treatment
duration was 3.1 months (range 2.6–12.1 months). PSA
declinewasobservedin5patients,butallofthemwere<50%
reduction and did not meet the criteria for partial response.
Figure 1 describes the best PSA response of each individual
patient on study in a waterfall plot. The summary statistics
of the distribution of PSA change are shown in Figure 2 by
a multiple box plot. Median PSA doubling time slowed from
4.7 months at baseline to 6.5 months during the treatment
with bevacizumab (Table 3).
Median time to PSA progression (TTPP) was 2.8 months
(90% CI 2.4–5.4 months), with six month TTPP rate of 19%
(90% CI 2–36%). The Kaplan-Meier curve of TTPP is shown
in Figure 3. Median time to new metastasis was 7.9 months
(90% CI 3.2–17.6 months), with 6-month and 12-month
metastasis-free survival rates of 59% and 35%, respectively
(Figure 4). Median time to bone metastasis was 10.6 months.
Only two patients have died to date; therefore it is
premature to analyze the OS data. Both deaths were related
to disease progression.
7. Discussion
Angiogenesis is one of the key mechanisms of tumor growth
and survival. Increased vascular density has been observed
in prostate cancer versus that noted in normal prostate
tissue [16]. Increased vascularity in the primary prostate
tumor was found to be associated with increased risk of
disease metastasis [17]. In mice xenograft models, beva-
cizumab monotherapy showed suppression of tumor growth
and prevention of metastasis [18]. Phase II trials revealed4 ISRN Oncology
Table 1: Baseline characteristics.
Patients (N = 15)
Median age (range) 70 (51–87)
Race Caucasian 9 (60%)
African American 6 (40%)
Performance status Zero 9 (60%)
One 6 (40%)
Prior local treatment
Prostatectomy 3 (20%);
radiation 14 (93%);
cryotherapy 1 (7%)
Other prior therapies
Antiandrogen 13 (86%)
Ketoconazole 3 (20%)
Steroid 2 (13%)
Gleason score
Six 4 (27%);
seven 4 (27%),
eight 1 (7%),
nine 6 (40%)
Median pretreatment PSA
[ng/mL] (range) 27 (2.6–104)
Median Hgb [g/dL] (range) 12.9 (9.9–15.5)
Table 2: Toxicities.
Gr 2 Gr 3 Gr 4
GU bleeding 1 (6.6%)
Thromboembolism 1 (6.6%)
Proteinuria 2 (13.3%) 1 (6.6%)
HTN 7 (46.6%) 2 (13.3%)
Diarrhea 1 (6.6%)
Nausea/vomiting 1 (6.6%)
Anemia 1 (6.6%)
promising eﬃcacy of bevacizumab containing therapy in
metastatic CRPC who had been previously heavily treated
with chemotherapies with PSA response rates of 55–63%,
objective response rates of 37–49%, and median survival
of 9 months or longer [11, 12]. However, recently reported
results of the phase III trial in metastatic CRPC revealed
that the addition of bevacizumab to standard docetaxel and
prednisone regimen improved PFS and response rate but
failed to demonstrate overall survival beneﬁt and increased
treatment-related deaths [19].
In our study, median TTPP and median time to new
metastasis were 2.8 and 7.9 months, respectively. These
estimated medians have wide conﬁdence intervals due to
the small sample size, but also reﬂect the heterogeneity of
this disease state which has made conducting clinical trials
extremely diﬃcult. Although the median PSA doubling time
was increased from 4.7 months before therapy to 6.5 months
duringbevacizumab,itisunknownifthischangewasdirectly
related to the bevacizumab use or not. Moreover, the clinical
signiﬁcance of this change is uncertain, and the prolongation
of PSA doubling time has not been clearly associated with
better clinical outcomes in nonmetastatic CRPC patients.
OurTTPPoutcometimepointsandmediantimetobone
metastases were relatively short compared to other clinical
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Figure 1: Waterfall plot of the PSA response distribution.
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Figure 2: Multiple box plot of the statistics of the PSA distributions
at various time points. The vertical lines represent range of PSA
with boxes indicating interquartile range. The horizontal lines in
the boxes represent median PSA and “+” represents mean value.
The numbers above the vertical lines are the number of patients.
The circle of week 18 represents one patient whose PSA value was
more than twice the interquartile range.
studies in this disease state and to historical data [8, 9, 20].
There are several possible explanations for this outcome.
First of all, our patients had multiple poor prognostic
features. All the patients had PSA doubling time of less than
10 months, and half of the patients had Gleason Score ≥ 8.
Secondly, our patient population had a higher proportion
of patients with locally advanced disease stage at diagnosis,
which explains why most patients had received radiation
therapy as the primary local therapy. Third, bevacizumab
may not be eﬀective enough to alter clinical outcomes in the
micrometastatic setting, in prostate cancer, especially given
the lack of OS beneﬁt in metastatic CRPC from the recently
published results of a phase III clinical trial [19]. One of the
mechanisms of action of bevacizumab is through its eﬀects
on stroma without direct cytotoxic eﬀect [21]. A perfect
example of a similar phenomenon is that, in colon cancer,
the addition of bevacizumab to cytotoxic chemotherapy
improvedoverallsurvivalinmetastaticdisease,butnotintheISRN Oncology 5
Table 3: PSA response.
N Median Min Max
PSA doubling
time (months)
pretreatment
15 4.7 0.8 9.9
PSA doubling
time (moths) on
therapy
15 6.5 0.8 29.4
adjuvant setting [22, 23]. Moreover, in a preclinical model,
bevacizumab was found to be less active against CRPC than
hormone-sensitive prostate cancer [24].
Nonmetastatic CRPC remains a challenging disease.
So far, several agents have been tested without successful
outcomes [20, 25, 26]. A large randomized phase III study
treated nonmetastatic CRPC patients with atrasentan, an
oral selective endothelin-A receptor antagonist, or placebo
[20]. Atrasentan improved time to disease progression
(similardeﬁnitiontothetimetonewmetastasisinourstudy)
from 22.4 months to 25.5 months, but the diﬀerence was
not statistically signiﬁcant (P = 0.288). The atrasentan study
also illustrated the diﬀerent practice patterns by regions.
Forty percent of US patients discontinued the treatment
prematurely primarily due to rising PSA whereas only 21.9%
of the patients in other countries did so. Some patients
and/or physicians may feel uncomfortable with continuing
the treatment knowing the rising PSA. We designed our
study protocol which would discontinue bevacizumab upon
PSA progression conforming to real practice in the USA.
This may have been a ﬂawed assessment since the impact of
bevacizumab monotherapy on PSA levels is unknown.
Another small randomized phase II study compared
pox-virus-based PSA vaccine with the antiandrogen, nilu-
tamide in nonmetastatic CRPC patients [26]. Possible sur-
vival beneﬁt was observed in those who received initial
immunotherapy,andalargerscalestudyiscurrentlyongoing
[27].
Denosumab is a monoclonal antibody against RANKL
and inhibits the osteoclast activity. Denosumab demon-
strated a delay in progression to bone metastasis in high-risk
nonmetastatic CRPC patients, which were deﬁned as PSA ≥
8ug/L and/or PSA doubling time ≤10 months [9]. However,
this change did not translate into an overall survival beneﬁt.
Furthermore, risk of osteonecrosis of jaw was 5% and the
quality-of-life impact of this adverse event on asymptomatic
patient, needs to be seriously considered.
Studying nonmetastatic CRPC is extremely diﬃcult due
to the heterogeneity of the population, the unpredictable
natural disease course, and the lack of established endpoints
toassesseﬃcacyofnovelagentsinthissetting.Thedeﬁnition
of “nonmetastatic” prostate cancer continues to change with
wider application of more sophisticated imaging techniques
such as magnetic resonance imaging (MRI) and positron
emission tomography (PET) scan [28]. Incidentally found
metastases are now detected in as many as 30% of asymp-
tomatic CRPC patients, which makes study screening failure
rateextremely high and causesslower accrual[29]. Including
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Figure 3: The Kaplan-Meier plot of the censored time to PSA
progression (TTPP) distribution.
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Figure 4: The Kaplan-Meier plot of the censored time to new
metastasis distribution.
speciﬁc high-risk subsets, based on Gleason Score or PSA
doubling time criteria, may help limit the heterogeneity in
the study population. Future studies will need to consider
stringent eligibility criteria.
The additional challenge in this population is that
patientsareasymptomaticandsubjectingthemtopotentially
toxic therapies requires careful consideration. Bevacizumab
is generally considered a well-tolerated biologic agent, but it
can potentially cause signiﬁcant side eﬀects, and 4 out of 15
patients in our study developed grade 3 or higher adverse
events. However, if safe and eﬀective treatment becomes
available, then the non-metastatic disease state represents
an ideal setting for intervention during this window of
opportunity.6 ISRN Oncology
Designing good clinical studies for nonmetastatic pros-
tate cancer is a dire need, and meeting the challenge of clini-
cal trial accrual in this asymptomatic but threatened patient
population should remain a priority.
8. Conclusion
In summary, bevacizumab monotherapy had only a modest
impact at best, on PSA doubling time and no clinical impact
in nonmetastatic CRPC patients. Further investigation of
bevacizumab monotherapy in prostate cancer is not indi-
cated.
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